A single centre, proof-of-concept clinical study for SM-88 in advanced metastatic cancer patients

Trial Profile

A single centre, proof-of-concept clinical study for SM-88 in advanced metastatic cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs SM 88 (Primary)
  • Indications Cancer
  • Focus First in man; Proof of concept; Therapeutic Use
  • Sponsors Tyme Technologies
  • Most Recent Events

    • 31 Jan 2017 Results published in a Tyme Technologies media release.
    • 28 Mar 2015 New trial record
    • 19 Mar 2015 According to a Tyme technology media release, it is anticipated that IND will be submitted to the FDA by the second quarter of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top